Production (Stage)
Bright Minds Biosciences Inc.
DRUG
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 74.68% | 30.44% | -25.39% | -17.24% | -35.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 549.12% | -5.44% | -51.51% | -116.89% | -76.02% |
| Operating Income | -549.12% | 5.44% | 51.51% | 116.89% | 76.02% |
| Income Before Tax | -382.70% | 102.86% | 51.77% | 114.47% | 71.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -382.70% | 102.86% | 51.77% | 114.47% | 71.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -382.70% | 102.86% | 51.77% | 114.47% | 71.91% |
| EBIT | -549.12% | 5.44% | 51.51% | 116.89% | 76.02% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -206.18% | 101.77% | 59.34% | 112.23% | 76.17% |
| Normalized Basic EPS | -206.21% | 101.79% | 59.35% | 112.23% | 76.18% |
| EPS Diluted | -203.53% | 101.76% | 58.81% | 112.13% | 75.92% |
| Normalized Diluted EPS | -206.21% | 101.64% | 59.35% | 111.73% | 76.18% |
| Average Basic Shares Outstanding | 57.68% | 60.45% | 18.62% | 18.34% | 17.86% |
| Average Diluted Shares Outstanding | 57.68% | 72.84% | 18.62% | 23.25% | 17.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |